Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$46.23M, compared with -$26.59M a year earlier. Trailing-twelve-month EBITDA was -$148.77M.
Context
- EBITDA amounted to 1102.9% of revenue in FY2025, up 47.5 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$161.51M (-49.8%) for the fiscal year ending Dec 2026, a slowdown from the -22.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$46.23M-9.8% QoQ
- Last fiscal yearDec 2025
- -$107.79M-22.6% YoY
- LTMJun 2026
- -$148.77M-62.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -73.9% | -60.2% | +13.7 pp |
| 1 year | -22.6% | -49.8% | -27.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (107.79M) USD
- Year-over-year change
- -22.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (107.79M) | -22.6% |
| FY2024 | 2024-12-31 | (87.95M) | +16.4% |
| FY2023 | 2023-12-31 | (105.2M) | +34.1% |
| FY2022 | 2022-12-31 | (159.73M) | +7.5% |
| FY2021 | 2021-12-31 | (172.6M) | — |
EBITDA vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 EBITDA of -$148.77M is the 6th highest of the 9 companies compared; the peer median is -$103.99M.
- Its year-over-year change of -62.6% is the 8th highest of 9, against a peer median of -9.5%.
- EBITDA amounts to 2712.3% of revenue for TSHA, versus a peer median of 261.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$53.46M | -44.4% | — | — | |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Jun 2026 | -$148.77M | -62.6% | — | 2712.3% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| Peer median (excluding TSHA) | -$103.99M | -9.5% | — | 261.2% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.5M | 15.45M | 8.33M | 9.77M |
| Cost of Revenue | 0 | 2.49M | 0 | 0 | 0 |
| Gross Profit | 0 | 15K | 15.45M | 8.33M | 9.77M |
| Gross Margin | — | 0.6% | 100.0% | 100.0% | 100.0% |
| Research & Development | 131.94M | 91.17M | 56.78M | 66M | 86.4M |
| Selling, General & Admin | 41.32M | 34.87M | 30.05M | 28.95M | 33.87M |
| Operating Expenses | 173.27M | 126.04M | 87.89M | 99.79M | 120.27M |
| Depreciation & Amortization | 492K | 2.49M | 1.37M | 1.25M | 1.15M |
| EBITDA | (172.6M) | (159.73M) | (105.2M) | (87.95M) | (107.79M) |
| EBITDA Margin | — | -6384.1% | -680.8% | -1055.5% | -1102.9% |
| Operating Income | (173.27M) | (126.03M) | (72.44M) | (91.46M) | (110.5M) |
| Operating Margin | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| Interest Income | 172K | 249K | 3.57M | 6.94M | 9.22M |
| Interest Expense | 1.43M | 3.8M | 5M | 102K | 63K |
| Other Income / Expenses | (1.26M) | (39.99M) | (39.13M) | 2.16M | 1.5M |
| Income Before Tax | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Pre-Tax Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Net Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (Basic) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| EPS (Diluted) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| Weighted Avg Shares | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
| Weighted Avg Shares (Diluted) | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.